[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:glycogen-storage-disease-due-to-acid-maltase-deficiency-late-onset":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":35,"states":36},"Glycogen storage disease due to acid maltase deficiency, late-onset",4,[7,15,22,29],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07282847","A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:44.395098Z","2026-07-24T01:27:14.897996Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07354724","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease",[19],"Phase 1","2026-08-26T02:19:04.543908Z","2026-05-13T02:55:06.697454Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT07123155","Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)",[26],"Phase 2","2026-08-26T02:17:05.997056Z","2026-05-05T02:43:27.592142Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT05989620","Long-Term Development of Muscular Dystrophy Outcome Assessments",[],"2026-08-26T02:18:01.700186Z","2026-05-13T02:55:06.399605Z",[],[37,40,44],{"state":38,"count":5,"slug":39},"Virginia","virginia",{"state":41,"count":42,"slug":43},"California",3,"california",{"state":45,"count":42,"slug":46},"North Carolina","north-carolina"]